The Chlamydia Market Is Anticipated to Grow with a Considerable CAGR In The 7MM During The Study Period (2019-32), Assesses DelveInsight
As per DelveInsight analysis in the Chlamydia Market Report, the disease awareness and emergence of new products in the pipeline will add to the Chlamydia market growth in the future. In addition, persistently rising cases of chlamydia in the forecast period will help increase the Chlamydia Infection diagnostics and therapeutics market.
LAS VEGAS, April 13, 2022 /PRNewswire/ -- DelveInsight's Chlamydia Market Insights report includes a comprehensive understanding of current treatment practices, Chlamydia emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM (the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan.
Key Takeaways from the Chlamydia Market
- According to DelveInsight estimates, the Chlamydia market size was USD 59.5 million in 2021, which is further expected to increase by 2032.
- As per estimates, there were approx 3.4 million Chlamydia diagnosed incident cases in the 7MM in 2021.
- Key Chlamydia companies such as Evofem Biosciences, QureTechBio, Vault Pharma, Aeterna Zentaris, Melinta Therapeutics, Abera Bioscience, Prokarium, Blue willow Biologics, Microbiotix, Abivax, and others are currently working to develop new drugs for Chlamydia which can be available in the Chlamydia market in the upcoming years.
- The Chlamydia therapies in the pipeline include EVO100, Chlamydia infection blockers (CIBs), VPI-201, Salmonella-Based Vaccine, and others.
- The increased number of chlamydia cases is likely to contribute directly to the Chlamydia market growth during the forecast period.
Discover more about therapies set to grab major Chlamydia market share @ Chlamydia Market Landscape
Chlamydia Overview
Chlamydial infection, caused by Chlamydia trachomatis, is the most prevalent bacterial sexually transmitted infection (STI). Age is a key predictor of risk for chlamydial infections, with the highest infection rates in women occurring between the ages of 15 and 24. As most people with the virus are asymptomatic, it is frequently left untreated, increasing the risk of transmission and catastrophic health implications for both sexes. The signs of Chlamydia vary from person to person and gender. The common Chlamydia symptoms generally arise two to six weeks following infection. The Chlamydia symptoms differ in men and women. The Chlamydia symptoms men include pain while urinating, pain in the testicles, burning and itching in the urethra, and others. On the other hand, the Chlamydia symptoms women include vaginal discomfort and bleeding, an abnormal discharge from the vagina, pain in the pelvis, and others.
The Aptima Combo 2 Assay and the Xpert CT/NG were the first Chlamydia test for extragenital diagnostic Chlamydia testing approved to identify the presence of the bacterium Chlamydia trachomatis via the throat and rectum. Previously, these assays were only approved for evaluating urine, vaginal, and endocervical materials. By allowing for additional screening, the availability of these two tests helps to meet an unmet public health need.
Chlamydia Epidemiology Segmentation
As per DelveInsight, there were approx 3.4 million Chlamydia diagnosed incident cases in the 7MM in 2021.
Among EU5 countries, Germany had the highest diagnosed incident cases of Chlamydia in 2021.
The Chlamydia Market Report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
- Diagnosed Incident Cases of Chlamydia
- Gender-specific Cases of Chlamydia
- Symptom-specific Cases of Chlamydia
- Age-specific Cases of Chlamydia
Download the report to understand which factors are driving Chlamydia epidemiology trends @ Chlamydia Epidemiological Insights
Chlamydia Treatment Market
Chlamydia treatment reduces harmful reproductive health problems as well as continuing sexual transmission. Furthermore, treating the sex partners reduces the risk of reinfection and infection of other partners. Additionally, treating pregnant women frequently prevents C. trachomatis in newborns during birth.
Recently, the FDA has approved The Binx Health IO CT/NG Assay for use in point-of-care settings to aid in the more rapid and appropriate treatment for Chlamydia. Access to speedier diagnostic findings and suitable therapies would help significantly in the fight against Chlamydia infections.
Moreover, the Centers for Disease Control and Prevention (CDC) recommends antibiotics for Chlamydia treatment, namely doxycycline, azithromycin, and levofloxacin. In addition to prescribing these Chlamydia medicines, doctors make some recommendations to ensure that the disease is completely cured, such as completing the course of antibiotics; not taking any other Chlamydia medication without consulting your healthcare professional, and refraining from any kind of sexual activity 7 days after single-dose antibiotics or until completion of a 7-day course of antibiotics for Chlamydia to avoid spreading the infection to partners.
Discover more about therapy set to grab substantial Chlamydia market share @ Chlamydia Treatment
Chlamydia Pipeline Therapies and Key Players
- EVO100: Evofem Biosciences
- Chlamydia infection blockers (CIBs): QureTechBio
- VPI-201: Vault Pharma
- Salmonella-Based Vaccine: Aeterna Zentaris
To know about more new drugs for Chlamydia treatment visit @ Chlamydia Medication
Chlamydia is by far the most prevalent reportable STI, with a high rate of occurrence that is expected to rise further in the future, necessitating treatment thereby boosting the Chlamydia market. A large number of asymptomatic cases remain undetected and as a result, the Chlamydia market might be significantly bigger than anticipated. In addition, the Chlamydia treatment guidelines and screening suggestions have been updated. Moreover, with the introduction of extremely sensitive and specific cost-effective diagnostic tools, diagnosis has become quick and straightforward which further drives the Chlamydia market.
Furthermore, a slew of Chlamydia therapies, including chlamydia infection blockers (CIBs), VPI-201, ABX196, and others, are in the early stages of development, paving the way for the future Chlamydia market. In addition, several other companies are also working to offer innovative products in the Chlamydia market.
However, Doxycycline treatment is inconvenient because individuals with a history of GERD must sit upright for 30 minutes after each dose. In addition, concerns have been raised about the efficacy of azithromycin for simultaneous rectal C. trachomatis infection, which can occur in women and cannot be anticipated by reported sexual activity. Both these factors are limiting the growth of the Chlamydia market. Moreover, the variety of chlamydia screening strategies making it difficult for doctors and researchers to determine which are beneficial are also impacting the Chlamydia market growth. In addition, there has been a scarcity of research linking chlamydial species to their final target host. As a result, this is acting as a barrier to the Chlamydia market growth. Moreover, there is no agreement on the best efficient approach to boost chlamydia screening which is another factor impacting the Chlamydia market.
Furthermore, antibiotic overuse, along with patient Chlamydia medication abuse, has resulted in the rise of antimicrobial-resistant (AMR) strains of Chlamydia trachomatis, thereby impeding the Chlamydia market size. In addition, noncompliance with prescribed drugs is a significant worry in a few circumstances along with a lack of understanding about chlamydia among patients and healthcare providers are also among the key factors impacting the Chlamydia market growth.
Scope of the Chlamydia Market Report
- Study Period: 2019-2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Chlamydia Companies: Evofem Biosciences, QureTechBio, Vault Pharma, Aeterna Zentaris, Melinta Therapeutics, Abera Bioscience, Prokarium, Blue willow Biologics, Microbiotix, Abivax, and others
- Key Chlamydia Therapies: EVO100, Chlamydia infection blockers (CIBs), VPI-201, Salmonella-Based Vaccine, and others
- Therapeutic Assessment: Chlamydia current marketed and emerging therapies
- Chlamydia Market Dynamics: Chlamydia market drivers and barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, Chlamydia Market Access and Reimbursement
Discover more about the future Chlamydia market share of treatment therapies @ Drugs used for Chlamydia Treatment
Table of Contents
1. | Key Insights |
2. | Report Introduction |
3. | Chlamydia Market Overview at a Glance |
4. | Executive Summary |
5. | Disease Background and Overview |
6. | Chlamydia Treatment and Management |
7. | Chlamydia Epidemiology and Patient Population |
8. | Patient Journey |
9. | Chlamydia Emerging Drugs |
10. | 7 Major Market Analysis |
11. | Chlamydia Market Outlook |
12. | Potential of Current and Emerging Therapies |
13. | KOL Views |
14. | Market Drivers |
15 | Market Barriers |
16. | Unmet Needs |
17. | SWOT Analysis |
18. | Appendix |
19. | DelveInsight Capabilities |
20. | Disclaimer |
21. | About DelveInsight |
Get in touch with our Business executive @ Healthcare Due Diligence Services
Related Reports
Chlamydia Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical, and forecasted Chlamydia epidemiology in the 7MM.
Chlamydia Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Chlamydia companies involved such as Evofem Biosciences, QureTechBio, Vault Pharma, among others.
Chlamydia Infections Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Chlamydia Infections companies involved such as Melinta Therapeutics, Abera Bioscience, Prokarium, Blue willow Biologics, Microbiotix, Abivax, among others.
Human Papillomavirus Infection Market
Human Papillomavirus Infection Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Human Papillomavirus Infection companies such as Vaccibody As, Genexine, Transgene, Inovio Pharmaceuticals, among others.
Human Immunodeficiency Virus Type 1 (HIV-1) Infection Market
Human Immunodeficiency Virus Type 1 (HIV-1) Infection Market Insights, Epidemiology, and Market Forecast-2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Human Immunodeficiency Virus Type 1 (HIV-1) Infection companies such as United BioPharma, Gilead sciences, Taimed Biologics, Merck, among others.
Genital Herpes Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Genital Herpes companies such as Immune System Regulation, United BioPharma, Heidelberg ImmunoTherapeutics, Genocea Biosciences, among others.
Other Trending Reports
Scabies Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Scabies companies in the domain.
Advanced Liver Cancer Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Advanced Liver Cancer companies in the domain.
Noonan Syndrome Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Noonan Syndrome companies in the domain.
Plasmacytoma Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Plasmacytoma companies in the domain.
West Nile Encephalitis Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key West Nile Encephalitis companies in the domain.
Latest Healthcare Blogs
Treatment-resistant Hypertension Market
Top Drugs Losing Patent in 2022
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect With Us at LinkedIn | Facebook | Twitter
Contact Us
Shruti Thakur
[email protected]
+1(919)321-6187
www.delveinsight.com
SOURCE DelveInsight Business Research, LLP
Share this article